Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disorder with a fatal outcome and a mean survival time ranging from 2 to 5 years.
1 No treatment is currently available to modify the disease process of ALS. Age,
2,3 site of onset,
2 functional and respiratory status,
4-6 cognitive dysfunction,
7 clinical phenotypes,
8,9 serum triglyceride and cholesterol levels,
10-12 creatinine level,
3,13 albumin level,
13 and
C9orf72 expansion
14 have been proposed as possible candidates associated with the prognosis of ALS. However, there is still no consensus on which biomarkers are reliable prognostic factors in ALS.
15